{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:21:31Z","timestamp":1791321691369,"version":"4.3.1"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:p>\n            Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) osteomyelitis. All treatment groups had less MRSA recovered than saline-treated animals.\n          <\/jats:p>","DOI":"10.1128\/aac.01703-21","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T17:05:33Z","timestamp":1635786333000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis"],"prefix":"10.1128","volume":"66","author":[{"given":"Melissa J.","family":"Karau","sequence":"first","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzannah M.","family":"Schmidt-Malan","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayawant N.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-1326","authenticated-orcid":true,"given":"Bobbi S.","family":"Pritt","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany R.","family":"Keepers","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":true,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104431"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00932-19"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1100533"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.14.64"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115568"},{"key":"e_1_3_2_8_2","first-page":"1","article-title":"In vitro and intracellular activities of omadacycline against Staphylococcus aureus isolates","volume":"5","author":"Dubois J","year":"2020","unstructured":"Dubois J, Dubois M, Martel JF. 2020. In vitro and intracellular activities of omadacycline against Staphylococcus aureus isolates. Intern Med Res Open J 5:1\u20136.","journal-title":"Intern Med Res Open J"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-019-00548-4"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.01.008"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2018.07.002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S171352"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01734-16"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01972-19"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-19"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_3_2_21_2","article-title":"In vitro activity of omadacycline against E. coli biofilms","author":"Diehl D","year":"2016","unstructured":"Diehl D, Bionda N, Cade N, Strickland A, Tanaska S. 2016. In vitro activity of omadacycline against E. coli biofilms. ASM Microbe 2016, Boston, MA","journal-title":"ASM Microbe 2016, Boston, MA"},{"key":"e_1_3_2_22_2","article-title":"Activities of omadacycline alone and in combination with rifampin against Staphylococcus aureus and Staphylococcus epidermidis in biofilm time kill analyses and a novel in vitro biofilm pharmacokinetic\/pharmacodynamic model","author":"Morrisette T","year":"2021","unstructured":"Morrisette T, Stamper K, Lev K, Kebriaei R, Holger D, Abul Mutakabbir J, Rybak MJ. 2021. Activities of omadacycline alone and in combination with rifampin against Staphylococcus aureus and Staphylococcus epidermidis in biofilm time kill analyses and a novel in vitro biofilm pharmacokinetic\/pharmacodynamic model. Eur Congr Clin Microbiol Infect Dis 2021 Virtual Conf","journal-title":"Eur Congr Clin Microbiol Infect Dis 2021 Virtual Conf"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01784-16"},{"key":"e_1_3_2_24_2","volume-title":"Nuzrya: highlights of prescribing information.","author":"Paratek Pharmaceuticals, Inc","year":"2018","unstructured":"Paratek Pharmaceuticals, Inc. 2018. Nuzrya: highlights of prescribing information. Reference ID 4329379. Paratek Pharmaceuticals, Inc., Boston, MA."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00740-10"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0029-2016"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa057"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa401"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000001152"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00959-19"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01275-20"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.02.005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.12.016"},{"key":"e_1_3_2_35_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2021","unstructured":"Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing, 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.20454\/jeaas.2019.1555"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05078-14"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00117-21"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01235-19"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01248-16"},{"key":"e_1_3_2_41_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. CLSI standard M07. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_42_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents.","author":"Clinical and Laboratory Standards Institute","year":"1999","unstructured":"Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents. CLSI document M26. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.05.010"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012775390-4\/50205-0"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01703-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01703-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:36:32Z","timestamp":1645486592000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01703-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,18]]}},"alternative-id":["10.1128\/AAC.01703-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01703-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"2021-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01703-21"}}